Mindful Body Awareness Training for Medication for Opioid Use Disorder (MOUD), Pacific Northwest, 2019-2024 (ICPSR 39235)
Version Date: Oct 8, 2024 View help for published
Principal Investigator(s): View help for Principal Investigator(s)
Cynthia Price, University of Washington-Seattle
https://doi.org/10.3886/ICPSR39235.v1
Version V1 (see more versions)
You are viewing an older version of this study. A newer version is available (view all versions)
Summary View help for Summary
The national opioid epidemic requires development of real-world evidence-based treatments for opioid use disorder, including adjuncts to Medication for Opioid Use Disorder (MOUD). Interventions are needed that address the complex needs of patients with opioid use disorder, which include substantial mental health co-morbidity and high rates of chronic pain. This study tested a mind-body intervention, Mindful Awareness in Body-oriented Therapy (MABT), as an adjunct to MOUD across multiple community outpatient clinical settings. MABT, a mindfulness-based intervention, addresses aspects of awareness, interoception, and regulation that may be associated with pain, mental health distress, and behavioral control that increase risk of relapse and poor treatment outcomes.
Citation View help for Citation
Export Citation:
Funding View help for Funding
Subject Terms View help for Subject Terms
Geographic Coverage View help for Geographic Coverage
Distributor(s) View help for Distributor(s)
Time Period(s) View help for Time Period(s)
Date of Collection View help for Date of Collection
Study Purpose View help for Study Purpose
The specific aims of this study were to evaluate the effectiveness of MABT + MOUD compared to MOUD only to:
- reduce opioid use and other illicit substances;
- improve mental and physical health; and
- improve interoceptive awareness and mindfulness skills.
Study Design View help for Study Design
Randomized, two-group (n = 165/165), repeated measures design comparing those who receive MABT and MOUD to MOUD only. Assessments were administered at baseline, post-intervention (3 months from baseline), and at 6, 9, and 12 months.
Sample View help for Sample
Individuals with opioid use disorder receiving medication for treatment were recruited to the study at six community clinics in the Pacific Northwest of the United States. Eligibility criteria included being over 18 years of age, and stable on medication (at least 2 months of treatment).
Time Method View help for Time Method
Universe View help for Universe
Adult individuals in treatment for opioid use disorder.
Unit(s) of Observation View help for Unit(s) of Observation
Data Type(s) View help for Data Type(s)
Mode of Data Collection View help for Mode of Data Collection
Description of Variables View help for Description of Variables
Variables in this study pertain to pain, drug use, and mental health. Demographic variables include gender and race.
Response Rates View help for Response Rates
303 individuals enrolled in the clinical trial.
Presence of Common Scales View help for Presence of Common Scales
Scales used in this study include the Timeline Followback interview, GAD-7, PHQ-9, PCL-5, BPI, MAIA, DERS-Short Form, and Frieberg Mindfulness Questionnaire (FMQ).
Hide